REG - Craneware plc - AGM Statement

CranewareAnnouncement

16/11/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231116:nRSP6203Ta&default-theme=true

RNS Number : 6203T  Craneware plc  16 November 2023

 

16 November 2023

 

Craneware plc

("Craneware" or the "Company" or the "Group")

 

AGM Statement

Craneware (AIM: CRW.L), the market leader in Value Cycle software solutions
for the US healthcare market, is pleased to provide an update on trading ahead
of its Annual General Meeting, which takes place at 10am today.

 

The Group has enjoyed continued positive financial and operational performance
since the start of the new financial year. The partner opportunities which
launched at the end of the last financial year continue to gather momentum and
the underlying sales pipeline continues to build, converting at an encouraging
rate into revenue. With financial results tracking in line with management
expectations, we look forward to providing a greater level of detail with our
next Trading Update, ahead of our Interim Results.

 

US hospitals are now returning their attention to providing Value-Based Care
and building resilience into their operating models through greater insights
into their financials and operations. Through Trisus, our cloud-based data
analytics and intelligence platform, we plan to be a central player in the
digitalisation, the use of data to provide insights that improve the
processes, of US healthcare. The team is focused on capturing this opportunity
through market expansion and the delivery of increased value to our extensive
hospital customer base.

 

We are confident that our resilient business model, extensive customer base,
high levels of Annual Recurring Revenue, together with our strategy for
delivering growth centred on the expansion of the Trisus platform, will enable
us to create further long-term value for all our stakeholders.

 

For further information, please contact:

 

 Craneware plc                                    +44 (0)131 550 3100
 Keith Neilson, CEO
 Craig Preston, CFO

 Alma (Financial PR)                              +44 (0)20 3405 0205
 Caroline Forde, Joe Pederzolli, Kinvara Verdon   craneware@almastrategic.com

 Peel Hunt (NOMAD and Joint Broker)               +44 (0)20 7418 8900
 Neil Patel, Paul Gillam, Richard Chambers

 Investec Bank PLC (Joint Broker)                 +44 (0)20 7597 5970
 Patrick Robb, Henry Reast, Cameron MacRitchie
 ( )
 Berenberg (Joint Broker)                         +44 (0)20 3207 7800
 Mark Whitmore, Richard Andrews, Dan Gee-Summons

 

 

About Craneware

 

The Craneware Group (AIM:CRW.L), the market leader in automated value cycle
solutions, including 340B management, collaborates with U.S. healthcare
providers to plan, execute, and monitor operational and financial performance
so they can continue to deliver quality care to their communities. Customers
choose The Craneware Group's Trisus data and applications platform as their
key to navigating the journey to financially sustainable value-based care.
Trisus combines revenue integrity, cost management, 340B performance, and
decision enablement into a single, SaaS-based platform. Trisus Chargemaster
secured top ranking in the Chargemaster Management category of the "2023 Best
in KLAS Awards: Software & Services" and is part of an extensive value
cycle management suite. The Craneware Group - transforming the business of
healthcare.

 

Learn more at www.thecranewaregroup.com (http://www.thecranewaregroup.com)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  AGMDBBDBCXBDGXU